Rochester Medical Corporation (ROCM) F3Q10 (Qtr End 06/30/10) Earnings Call Transcript July 29, 2010 4:30 pm ET Executives Anthony Conway – Chairman, CEO and President David Jonas – CFO, Treasurer and Secretary Analysts Tyson Bauer – Wealth Monitors Incorporated Beth Lilly – Gabelli Michael Boulgaris – Boulgaris Investments Presentation Operator
Previous Statements by ROCM
» Rochester Medical F2Q10 Earnings Call Transcript
» Rochester Medical F1Q10 (Qtr End 12/31/09) Earnings Call Transcript
» Rochester Medical F4Q09 (Qtr End 9/30/09) Earnings Call Transcript
Rochester Medical branded sales rose 35% on a constant currency basis. The branded growth continues to be led by strong sales of our all-silicone MAGIC3 and Hydrosil layered hydrophilic intermittent catheters, and our new Strata brand Foley catheters. We have only a very small market share with these products and we expect excellent growth to continue going forward.We feel very good about the FemSoft pilot activity, both here in the United States and in the United Kingdom. In the U.S., we have concluded that the clinical sell through urologists, urogynes, and gynecologists is the most effective approach to market and we plan to expand our domestic extended care sales force to take dual advantage of the MAGIC3 and FemSoft opportunity on combined sales calls. Clinicians react favorably to both product lines and we believe that the addition of FemSoft to the call will work very well for both products. We said earlier in the year that we expected the U.S. FemSoft reimbursement rate to be finalized by the end of July. This is not yet the case. CMS has had several errors and mix-up regarding reimbursement procedures and processes for the device. We are working with them to get it resolved and we believe we will have final reimbursement established in the near term. FemSoft introduction in the United Kingdom is off to a good start with some early adopting clinicians writing multiple prescriptions and speaking very highly of the device. As an example, we had one clinician over there that so far has written 29 prescriptions; that's just from a single clinician. That's not normal, that's the highest we've got, just to make clear, but we do have clinicians that are very, very excited about the device. We believe that FemSoft is a natural fit for the U.K. health care system where conservative approaches to controlling incontinence are generally preferred to surgery. As we said in the press release, it is still too early to predict the market potential for the device, but we are far enough along to now have confidence in the FemSoft as a viable and integral addition to our product lines, both in the United States and the United Kingdom. We are also in discussion with interested potential distributors in other countries.
Now, let me turn it over to Dave and he will give you further insight into the numbers. Dave?David Jonas Thanks, Anthony. I'm going to spend a few minutes highlighting a few results reflected in our just-released third quarter fiscal 2010 earnings release. First, our sales. For ease of discussion, unless otherwise noted, all sales information will be discussed in constant currency. I’m doing this to exclude the impact of foreign currency exchange, which will show a true reflection of our sales growth. As Anthony has explained, our sales results for the third quarter showed very good overall growth, especially in our key branded markets in the U.S., U.K., and the rest of Europe. As we have discussed in the last couple of years, we are focused on and have increased our investments and activity in our worldwide branded sales. This has been done for many reasons, including better market access, changing reimbursement rules, and an increased clinical demand for infection reducing in all-silicone, non-latex, and non-PVC devices. We call this our investment in growth strategy and the results have been positive. These investments and focus fueled the growth in our worldwide branded sales, which were a record $7.6 million this quarter versus $5.6 million last year, an increase of 35% for the third quarter. This 35% increase included 66% growth in worldwide intermittent sales, a 33% increase in worldwide Foley catheter sales, and a 16% increase in male external catheter sales. Our branded sales accounted for 74.2% of our total sales in the third quarter, also an all-time high for Rochester Medical. Read the rest of this transcript for free on seekingalpha.com